163 related articles for article (PubMed ID: 37858132)
21. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
22. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract][Full Text] [Related]
23. Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.
Mihai A; Mu Y; Armstrong J; Dunne M; Beriwal S; Rock L; Thirion P; Heron DE; Bird BH; Westrup J; Murphy CG; Huq MS; McDermott R
J Radiosurg SBRT; 2017; 5(1):43-53. PubMed ID: 29296462
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
25. Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer.
Ottaiano A; Caraglia M; Di Mauro A; Botti G; Lombardi A; Galon J; Luce A; D'Amore L; Perri F; Santorsola M; Hermitte F; Savarese G; Tatangelo F; Granata V; Izzo F; Belli A; Scala S; Delrio P; Circelli L; Nasti G
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33096795
[TBL] [Abstract][Full Text] [Related]
26. Imaging of Oligometastatic Disease.
Vietti Violi N; Hajri R; Haefliger L; Nicod-Lalonde M; Villard N; Dromain C
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326586
[TBL] [Abstract][Full Text] [Related]
27. Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment.
Santorsola M; Capuozzo M; Savarese G; Ianniello M; Petrillo N; Casillo M; Sabbatino F; Perri F; Ferrara F; Zovi A; Berretta M; Granata V; Nasti G; Ottaiano A
Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136953
[TBL] [Abstract][Full Text] [Related]
28. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
29. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
30. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
32. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.
Inoue Y; Fujishima M; Ono M; Masuda J; Ozaki Y; Maeda T; Uehiro N; Takahashi Y; Kobayashi T; Sakai T; Osako T; Ueno T; Ohno S
Breast Cancer Res Treat; 2022 Nov; 196(2):341-348. PubMed ID: 36153381
[TBL] [Abstract][Full Text] [Related]
34. Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers.
Zhao Y; Li J; Li D; Wang Z; Zhao J; Wu X; Sun Q; Lin PP; Plum P; Damanakis A; Gebauer F; Zhou M; Zhang Z; Schlösser H; Jauch KW; Nelson PJ; Bruns CJ
Semin Cancer Biol; 2020 Feb; 60():334-343. PubMed ID: 31445220
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
36. Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy.
Chen H; Poon I; Atenafu EG; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):892-901. PubMed ID: 34890753
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
38. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
40. A risk-based approach to identifying oligometastatic disease on imaging.
deSouza NM; Tempany CM
Int J Cancer; 2019 Feb; 144(3):422-430. PubMed ID: 30098215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]